Pinokalant_product_DataBase

Bioactivity	Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity[1].
In Vivo	Pinokalant significantly reduces cortical infarct volume from 33.8 mm3 to 24.5 mm3[1].
Name	Pinokalant
CAS	149759-26-2
Formula	C41H48N2O9
Molar Mass	712.83
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Christensen T, et al. The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin Pharmacol Toxicol. 2005 Apr;96(4):316-24. [2]. Simard JM, et al. Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta. 2007 Aug;1772(8):947-57. [3]. Serdar Durdagi, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. 2020.

PeptideDB